Concise Prescribing Info
Octreotide acetate
Symptomatic control & reduction of GH & IGF-1 plasma levels in patients w/ acromegaly who are inadequately controlled by surgery & radiotherapy. Acromegalic patients unfit or unwilling to undergo surgery, or in interim period until radiotherapy becomes fully effective. Symptomatic relief associated w/ functional gastro-entero-pancreatic (GEP) endocrine tumors eg, carcinoid tumors w/ carcinoid syndrome features, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, insulinomas, GRFomas. Prevention of complications following pancreatic surgery. Emergency management of bleeding gastroesophageal varices in patients w/ cirrhosis.
Dosage/Direction for Use
Acromegaly Initially 0.05-0.1 mg SC every 8 or 12 hr. Max: 1.5 mg daily. GEP endocrine tumors Initially 0.05 mg SC once or bd, may be gradually increased to 0.1-0.2 mg tds. Complications following pancreatic surgery 0.1 mg SC tds for 7 consecutive days, starting operation day at least 1 hr before laparotomy. Bleeding gastro-oesophageal varices 25 mcg/hr for 5 days by continuous IV infusion. Cirrhotic patient w/ bleeding gastro-esophageal varices Up to 50 mcg/hr for 5 days.
Special Precautions
Not an anti-tumor therapy. CV-related events; impaired post-prandial glucose tolerance, hypoglycemia; increased risk of insulin-dependent diabetes, insulin requirement changes; local site reactions. Perform ultrasonic gallbladder exam prior to & at about 6-12 mth intervals during therapy. Monitor thyroid function during prolonged treatment; vit B12 levels in patients w/ history of vit B12 deprivation; blood glucose levels in patients treated for bleeding gastro-oesophageal varices. Hepatic cirrhosis. Women of childbearing potential should use effective contraception during treatment. Pregnancy. Not to be used during lactation. Childn <18 yr.
Adverse Reactions
Hyperglycaemia; headache; diarrhoea, abdominal pain, nausea, constipation, flatulence; cholelithiasis; inj site reaction. Hypothyroidism, thyroid disorder eg, decreased TSH, total & free T4; hypoglycaemia, impaired glucose tolerance, decreased appetite; dizziness; bradycardia; dyspnoea; dyspepsia, vomiting, abdominal distension, steatorrhoea, loose stools, discolored faeces; cholecystitis, biliary sludge, hyperbilirubinaemia; pruritus, rash, alopecia; asthenia; increased transaminase.
Drug Interactions
Reduced intestinal absorption of ciclosporin, cimetidine. Increased bioavailability of bromocriptine. Decreased metabolic clearance of other CYP3A4-metabolized drugs & w/ low therapeutic index eg, quinidine, terfenadine.
MIMS Class
Other Gastrointestinal Drugs / Trophic Hormones & Related Synthetic Drugs
ATC Classification
H01CB02 - octreotide ; Belongs to the class of antigrowth hormone. Used in hypothalamic hormone preparations.
Sandostatin soln for inj 0.05 mg/mL
5 × 1's
Sandostatin soln for inj 0.1 mg/mL
5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in